The creation of a silica nanocapsule will allow therapies that use light or phototherapies, to treat other from of cancers. Silica nanoparticles will allow the use of near-infrared (NIR) more effectively. The nanoparticles will convert NIR into visible light triggering a chemical reaction and releasing reactive oxygen species (ROS) to attack the unhealthy tissue.
The study was conducted at the INRS (Institut national de la recherche scientifique) professors Fiorenzo Vetrone and Federico Rosei, in collaboration with an international research team. Their results have been published in an article featured on the cover of the 26th edition of the Royal Society of Chemistry journal Chemical Science.
Photodynamic therapies, referred to as PDT, are treatments that use visible light to destroy cancerous or precancerous cells. Abnormal tissue is brought into contact with a light-activated and light-sensitive medication before it is exposed to light, triggering a chemical reaction that releases reactive oxygen species (ROS) to attack the diseased cells. In current treatments, the medication is injected into unhealthy tissue. But injection only works if tumors are on or under the skin, such as skin cancers.
Developed by a team of chemists, magnetic resonance imaging (MRI) experts, and an oncologist, the new way of selectively enveloping light-sensitive medication in a nanocapsule could be beneficial for diagnosis and treatment. "Eventually, nanocapsules will help us expand the scope of application," added the professor.
Next, the team plans to test the nanoparticles in an in-vivo setting.